Two cysteine protease inhibitors, EhICP1 and 2, localized in distinct compartments, negatively regulate secretion in Entamoeba histolytica  by Sato, Dan et al.
FEBS Letters 580 (2006) 5306–5312Two cysteine protease inhibitors, EhICP1 and 2, localized in
distinct compartments, negatively regulate secretion in
Entamoeba histolytica
Dan Sato, Kumiko Nakada-Tsukui, Mami Okada, Tomoyoshi Nozaki*
Department of Parasitology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
Received 9 August 2006; revised 27 August 2006; accepted 28 August 2006
Available online 12 September 2006
Edited by Stuart FergusonAbstract The enteric protozoan parasite Entamoeba histolytica
uniquely possesses two isotypes of ICPs, a novel class of inhibi-
tors for cysteine proteases. These two EhICPs showed a remark-
able diﬀerence in the ability to inhibit cysteine protease (CP) 5, a
well-established virulence determinant, whereas they equally
inhibited CP1 and CP2. Immunoﬂuorescence imaging and cellu-
lar fractionation showed that EhICP1 and EhICP2 are localized
to distinct compartments. While EhICP1 is localized to the sol-
uble cytosolic fraction, EhICP2 is targeted from lysosomes to
phagosomes upon erythrocyte engulfment. Overexpression of
either EhICP1 or EhICP2 caused reduction of intracellular
CP activity, but not the amount of CP, and decrease in the secre-
tion of all major CPs, suggesting that both EhICPs are involved
in the traﬃcking and/or interference with the major CP activity.
These data indicate that the two EhICPs, present in distinct sub-
cellular compartments, negatively regulate CP secretion, and,
thus, the virulence of this parasite.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Cysteine proteases (CPs) represent a broad class of proteo-
lytic enzymes widely distributed among living organisms and
play major roles in various biological processes [1]. The proto-
zoan parasite Entamoeba histolytica, the causative agent of hu-
man amoebiasis [2], invades the intestinal epithelium and
causes amoebic dysentery, colitis, and abscesses in liver, lung,
and brain [3]. Papain-family CPs (EC 3.4.22) have been
known as one of the virulence factors of this parasite [4].
Among >40 CP genes present in this organism [5,6], CP1,
CP2, and CP5 are most highly expressed and contribute to
about 90% of the total CP activity of the amoeba [7]. It has
been recently shown that expression of individual CPs is con-Abbreviations: E-64, trans-epoxysuccinyl-L-leucyl-amido (4-guanidino)
butane; Z-RR-MCA, benzyloxycarbonyl-Arg-Arg-7-amino-methyl-
coumarin; GFP, green ﬂuorescent protein; HA, hemagglutinin; TCA,
trichlororoacetic acid; Mab, monoclonal IgG
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doi:10.1016/j.febslet.2006.08.081trolled independently. For instance, expression of CPs includ-
ing CP4 and CP6 drastically increased (6–35-fold) upon
animal intestinal infection, while expression of CP8 decreased
by 5–14-fold [8]. It was also shown that heat shock at 42 C
also down-modulated expression of CP1, CP2, and CP8 by
6–9-fold while it up-regulated expression of CP6 and CP4
by 9- and 4-fold, respectively [9]. CP5 has been implicated
to play a major role in the pathogenicity since antisense
knockdown of CP5 expression reduced both in vitro and
in vivo virulence [10,11] and CP5 gene is degenerated in a
genetically related but non-pathogenic E. dispar species [5,7].
Since the incubation of trophozoites with a synthetic CP
inhibitor, trans-epoxysuccinyl-L-leucyl-amido (4-guanidino)
butane (E-64), inhibited the formation of liver abscess [12],
CPs has been viewed as an attractive chemotherapeutic target.
Although biological and pathological importance of the
amoebic CPs has been extensively studied, it remains poorly
understood how the activity of CPs is regulated so that these
highly competent hydrolases with a wide substrate speciﬁcity
elicit activity for speciﬁc and only desired biological processes
[13]. A variety of classes of protease inhibitors that regulate
CPs have been reported [1] (see MEROPS peptidase database
(http://merops.sanger.ac.uk/)).
A novel class of proteinaceous CP inhibitors, named chaga-
sin or inhibitor for CP (ICP), have been recently discovered in
parasitic protozoa including Trypanosoma cruzi [14], Leish-
mania mexicana [15], L. major, T. brucei, E. histolytica, Cryp-
tosporidium parvum, bacteria, and archaea [16]. It was shown
that ICP inhibited papain-family CPs with an inhibition con-
stant (Ki) of a nano to picomolar range [14], similar to cysta-
tin [17]. Structural analyses by NMR revealed that chagasin
and L. mexicana ICP consisted of eight b-strands and one
small a-helix, and three mobile loops in the same side bound
to CP [18,19]. Chagasin has been shown to regulate diﬀerenti-
ation and invasion of mammalian cells [20]. In L. mexicana,
ICP has been assumed to play a role in the protection against
a hydrolytic environment in insect vectors or hosts [15]. Dis-
similar to other organisms, E. histolytica possesses two iso-
types of ICP, and signiﬁcance of this apparent redundance
is not understood. In this study, we describe the characteriza-
tion of two EhICPs, designated EhICP1 [21] and EhICP2,
which shows distinct biochemical properties and intracellular
localization. We also show, using the amoeba cell lines
overexpressing epitope-tagged EhICPs, that both EhICPs
are involved in the negative regulation of the secretion of
CPs.blished by Elsevier B.V. All rights reserved.
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2.1. Parasite and culture conditions
Trophozoites of E. histolytica HM-1:IMSS cl-6 were cultured axeni-
cally in BI-S-33 medium at 35.5 C [22].
2.2. Expression and puriﬁcation of recombinant EhICPs
EhICP sequences were obtained from the E. histolytica genome
database at the Wellcome Trust Sanger Institute (http://www.san-
ger.ac.uk/Projects/E_histolytica/). A entire coding region of EhICP1
gene, or a part of EhICP2 gene lacking a putative signal sequence,
was ampliﬁed by PCR with oligonucleotide primers (Supplementary
Table) and the trophozoite cDNA as a template. The obtained PCR
products were inserted into pET100/D-TOPO expression vector (Invit-
rogen). Histidine-tagged EhICPs were puriﬁed from the soluble lysate
of E. coli strain BL21(DE3) transformed with the resulting plasmids
with aﬃnity chromatography using HisTrap HP columns (GE Health-
care Bio-Sciences). EhICP1 or EhICP2 was further puriﬁed using a
MonoQ 5/5HR or MonoS 5/5HR column (GE Healthcare Bio-Sci-
ences), respectively, preequilibrated with 50 mM ethanolamine,
pH8.5, with a linear gradient of 0–1 M NaCl at a ﬂow rate of
1.0 ml/min. The eluted recombinant EhICP1 and EhICP2 were esti-
mated to be >95% pure by SDS–PAGE analysis (data not shown).
The histidine tag at the amino terminus of recombinant EhICPs was
removed by enterokinase and EK-Away resin (Invitrogen).2.3. Production of antibody
Antisera were raised against puriﬁed recombinant EhICP1 and
EhICP2 in rabbits commercially. IgGs were further puriﬁed with a
ProteinG-Sepharose column (GE Healthcare Bio-Sciences).
2.4. Identiﬁcation of targets of EhICPs
The trophozoite lysate (120 lg) was incubated with histidine-tagged
EhICP1 (290 ng), EhICP2 (290 ng), or E-64 (280 lM) in 300 lL of buf-
fer A (50 mM sodium phosphate buﬀer (pH 7.2), 150 mM NaCl,
50 mM imidazole, 1 mM DTT, and 0.5% Triton X-100) at 4 C for
2 h. After 10 lL of HisTrap HP beads (50% slurry) was added, the
mixtures were rotated gently at 4 C for 12 h. After the beads were
extensively washed with buﬀer A containing 350 mM NaCl, the bound
proteins were subjected to SDS–PAGE and immunoblot analyses with
anti-CP2 and anti-CP5 IgGs, which were a generous gift by Sharon L.
Reed [23], and Iris Bruchhaus, Mathias Leippe, and Egbert Tannich
[11], respectively.2.5. Production and activation of recombinant CPs
CP1, 2, and 5 genes lacking the putative signal sequences were ampli-
ﬁed by PCR using oligonucleotide primers (Supplementary Table) de-
signed based on available nucleotide sequences (Q01957 (CP1),
Q01958 (CP2), and AAFB01000593 (CP5)) and trophozoite cDNA.
PCR products were inserted into pET-15b expression plasmid (Nova-
gen). Histidine-tagged recombinant CP proteins were produced as
inclusion body in E. coli strain BL21(DE3). Recombinant CP proteins
were puriﬁed by aﬃnity chromatography under denaturing conditions.
Refolding and activation were performed as previously described [24]
with some modiﬁcations. Brieﬂy, recombinant CP1 and CP2 (100 lg/
ml, 30–40 lL) were dialyzed against refolding buﬀer B (100 mM Tris–
HCl (pH 8.8), 300 mM NaCl, 5% glycerol, 0.1 mM EDTA, 3 mM re-
duced glutathione and 0.5 mM oxidized glutathione) at 4 C for
1.5 h, and subsequently against refolding buﬀer C (25 mM Tris–HCl
(pH 6.8), 150 mMNaCl) at 4 C for 1.5 h. Recombinant CP5 was trea-
ted similarly except that refolding buﬀer B contained 50 mM Tris–HCl
(pH 8.8) and refolding buﬀer C contained 50 mM Tris–HCl (pH 6.8)
without NaCl. Refolded recombinant CPs were activated by the incu-
bation with an equal volume of 100 mM Tris–HCl (pH 8.8), 20 mM
DTT and 2% Triton X-100 at 37 C for 30 min.
2.6. Measurement of inhibition constants of EhICPs
Activated recombinant CPs or the trophozoite lysate (a ﬁnal concen-
tration of 1.56 or 22.6 lg/ml, respectively) were incubated with various
concentrations of the puriﬁed recombinant EhICP1 or EhICP2 in
150 mM sodium acetate buﬀer (pH 5.0), 1 mM DTT and 1 mM EDTA
at 37 C for 30 min. Subsequently, benzyloxycarbonyl-Arg-Arg-7-ami-
no-methylcoumarin (Z-RR-MCA) (Peptide Institute Inc.) was addedat a ﬁnal concentration of 100 lM. Hydrolysis of the ﬂuorescent sub-
strate was estimated by measuring emission at 460 nm with excitation
at 355 nm. The apparent equilibrium constants (Ki app) for inhibition
were calculated by a slope of [I]/(1  vi/vo) versus vo/vi, where vi or vo
represents the steady-state velocity with or without an inhibitor,
respectively [25]. The true Ki values were calculated from Ki app =
Ki/(1+[S]/Km), with a Km value measured independently.
2.7. Estimation of the ratio of CPs to ICPs
The ratio of CPs to ICPs was determined by titration of CPs with E-
64 or papain with heat-stable ICPs (data not shown) as previously
shown [20] with minor modiﬁcation. Brieﬂy, to measure CP concentra-
tions the trophozoite lysate (a ﬁnal concentration, 2.50 lg/mL) was
incubated with various concentrations of E-64 for 30 min at 37 C,
and the remaining CP activity was measured as described above. In or-
der to estimate ICP concentrations, the lysate was boiled for 10 min to
inactivate CPs and centrifuged at 15000 · g for 10 min at 4 C. The
serially diluted supernatant was incubated with papain (a ﬁnal concen-
tration, 162.6 nM) for 30 min at 37 C, and the remaining CP activity
was measured. Molar concentration was calculated by linear regression
of [I] on the x-axis and vo on the y, at which vo = zero.
2.8. Creation of cell lines overexpressing an epitope-tagged EhICP1,
EhICP2, or CP5
A full-length EhICPs and CP5 genes ampliﬁed by PCR with oligo-
nucleotide primers (Supplementary Table) were inserted into pKT-
C 0GFP, pKT-C 0HA or pKT-N 0HA plasmid. They are the derivatives
of pEhEx [26], which allow expression of a gene of interest as car-
boxyl-terminal fusion with GFP (pKT-C 0GFP), or with three tandem
repeats of the HA peptide fused at the amino (pKT-N 0HA) or carboxyl
terminus (pKT-C 0HA). Transformation and selection of transformants
were previously described [27,28].
2.9. Preparation of cell lysates and culture supernatants
Semi-conﬂuent cultures were harvested at 24–48 h after initiation of
cultures and resuspended in BI-S-33 medium without bovine serum at
a concentration of 5 · 105 cells/ml. After the cultures (2.0 ml) were
incubated at 35.5 C for 2 h, culture supernatants were centrifuged at
15000 · g for 10 min. Attached trophozoites were rinsed with ice-cold
PBS containing 2% glucose, and collected by centrifugation at 1000 · g
for 10 min. The culture supernatants were dialyzed twice against PBS
containing 0.2% Triton X-100 for 2 h for measurement of CP activity,
and concentrated to 10-fold with trichlororoacetic acid (TCA)–acetone
precipitation for Western Blot analysis.
2.10. Indirect immunoﬂuorescence microscopy
Immunoﬂurorescence imaging was carried out with Carl Zeiss
LSM510 conforcal laser-scanning microscope as previously described
[26]. Acidic compartments of trophozoites were stained with LysoTrac-
ker RED DND-99 (Invitrogen) at 35.5 C for 12 h. After trophozoites
were incubated with gerbil erythrocytes (1 · 107/ml) at 35 C for
10 min, they were ﬁxed, permealized, and reacted with anti-EhICP2
IgG or anti-HA 16B12 monoclonal IgG (Mab) (Berkeley Antibody)
as previously described.
2.11. Cell fractionation
Cell fractionation was performed as previously described [29] at 4 C
with modiﬁcations. Brieﬂy, the trophozoites were gently disrupted in
an isotonic buﬀer (200 mM mannitol, 50 mM sucrose, 10 mM KCl,
1 mM EDTA, 10 mM HEPES, protease inhibitor cocktail (Roche))
using a Dounce glass homogenizer. The lysate was centrifuged at
5000 · g for 10 min at 4 C. The supernatant was subsequently ultra-
centrifuged at 100000 · g for 20 min at 4 C. These supernatants and
pellets were subjected to immunoblot analyses with anti-EhICP1,
anti-EhICP2, anti-NifU [30], anti-CP5, and anti-Hgl IgGs the last of
(a gift by Barbara J. Mann and William A. Petri, Jr.) [31].3. Results and discussion
While E. histolytica possesses >40 CPs that belong to papain
family, it apparently lacks common CP inhibitors including
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Fig. 2. Immunoblot analysis of EhICPs in or secreted by EhICP-
overexpressing transformants. The cell lysates (18 lg) or the culture
supernatants (CS, 70 lL, concentrated with TCA–acetone precipita-
tion) of control or EhICP-overexpressing transformants were boiled
with 2% SDS and 2% b-mercaptoethanol and subsequently analyzed
with western blotting using anti-EhICP1 (panel A) or anti-EhICP2 IgG
(panel B). (A) Lane 1, an irrelevant control transformant; lane 2, N 0-
HA-EhICP1; lane 3, EhICP1-C0-GFP. The endogenous EhICP1 is
indicated by a thick arrow, while HA-tagged (lane 2) and GFP-tagged
(lane 3) EhICP1 are indicated by thin arrows. (B) Lane 1, an irrelevant
control transformant; lane 2, EhICP2-C0-GFP. The endogenous
EhICP2 is indicated by an open or a ﬁlled thick arrow, while GFP-
tagged EhICP2 is indicated by a thin arrow.
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of CPs in this parasite, we searched for the E. histolytica homo-
logues of a new class of CP inhibitors recently discovered in
other parasitic protists including T. cruzi [14] and L. mexicana
[15]. We found two independent putative ICP genes in the E.
histolytica genome database, one of which was previously
characterized (EhICP1 [21]). The second ICP, which we desig-
nated EhICP2 in this study, was identical to one previously
identiﬁed by the other group. [16]. We found a homolog of
EhICP2, but not EhICP1, in the current genome database of
E. dispar, a closely-related but non-pathogenic species, and
E. invadens, a reptilian species. The completion of the genome
of these organisms should clarify whether EhICP1 is uniquely
present only in E. histolytica.
EhICP2 showed 28% identity to EhICP1, 24–31% identity to
ICPs from kinetoplastids, and 20–27% identity to ICPs from
bacteria, e.g. Clostridium, Coxiella, Legionella, and Pseudomo-
nas, and archaea, e.g. Methanosarcina. Alignment of ICPs
from various organisms revealed unique features of EhICP2.
First, EhICP2 possesses a putative signal sequence (Fig. 1,
underlined), similar to ICP from related reptilian E. invadens
and human apicomplexan C. parvum, suggestive of intracellu-
lar transport and/or secretion. Second, threonine of the CP
binding motif NPTTG, which attacks the active cysteine di-
rectly [18,19] and is conserved among all ICPs available in
the database including EhICP1 (indicated by asterisk), is
substituted with serine in EhICP2 as well as in E. invadens
ICP [32].
Immunoblot analysis showed endogenous EhICP2 protein
as 14- and 25-kDa bands in the lysate boiled under reducing
conditions (Fig. 2B, ﬁlled and open thick arrows, respectively).
This result suggests the following possibilities: (1) a fraction of
EhICP2 covalently binds to other not-yet-identiﬁed protein(s);
(2) EhICP2 possesses unknown post-translational modiﬁca-
tions; or (3) EhICP2 forms dimer resistant to heat and reduc-
ing agents. It is unlikely that 25-kDa band is a complex of
EhICP2 and CPs because EhICPs and CPs were dissociated
under the denaturing and reducing conditions and a mature
form of CPs are approximately 30 kDa (see below, Figs. 3EhICP2 1 ---------------MKQFIFFALLCTSTYAAI
EhICP1 1 ---------------------------------
E.invadens ICP 1 ----------------MGVIVFVALLTISWAET
chagasin 1 -------------------------------MS
T.brusei ICP 1 ------------------------------MSH
L.mexicana ICP 1 -------------------------------MI
L.major ICP 1 ---------------------------MQPKMT
C.parvum ICP 1 MNKTIFRLLFFFAIYIMIGISNA(32aa)INVQ
EhICP2 61 FSLSQDTIKAEPHPSG------MVGFPSIREI
EhICP1 42 LSNTVEYVADQHAPG-------ICGCGGKYHI
E.invadens ICP 60 LQLLDHKITENKEN--------IPGSNFDEVW
chagasin 51 FTVENKYFPPDSK---------LLGAGGTEHF
T.brusei ICP 52 FAIQSKFNNRAPHDNHKNHRRLLVGAGGTMVL
L.mexicana ICP 52 LEVVCKYTPT-PSST------PMVGVGGIYVV
L.major ICP 56 LEVTSKYTPK-PVSG------SMVGAGGSYTV
C.parvum ICP 107 IDAEPSYVPD-PHPEG------MVGYGGKYTF
Fig. 1. Alignment of deduced protein sequences of ICPs from various parasi
invadens (contig 206103 of the E. invadens Sequencing Project at The Wellc
(AJ548777), L. mexicana (AJ548776), L. major (CAC01987), and C. parvum (E
predicted with SignalP [35] are underlined. Amino acids that are identic
corresponding to the three loops that bind to CP are indicated by dotted line
with asterisks [18,19].and 4B) [4]. The observed two forms of EhICP2 contradict
with the single EhICP2 shown in the recent report [33]. How-
ever, a reason of this discrepancy is currently unknown. C 0-
GFP-fused EhICP2 was detected as doublet around 40 kDa,
which agreed with a predicted molecular mass. The nature of
the doublet C 0-GFP-fused EhICP2 is not well understood. In
contrast, a single intrinsic EhICP1 protein of a predicted size
(13 kDa) was detected, as previously reported [21]. N 0-HA
EhICP1 was detected as a 20-kDa band due to the addition
of an amino-terminal HA tag (4.6 kDa) while two bands cor-
responding to C 0-GFP-fused EhICP1 were detected around*****
HILTEKEDHATLHISFNDLIKIQLRTNPSTGYAWNIEYPTD-------T
MSLTEDNNNTTITIAKGENKEIILHGNPTTGYSWVVDSCEG--------
YKITLENNGQLFNFKNGEEFDVVLVTNPSTGHNWELETNNR-------H
HKVTKAHNGATLTVAVGELVEIQLPSNPTTGFAWYFEGGTK-ESPNESM
NLFTEEDNNKTIRMVIGETFTIELKSNPTTGYTWLRSGLAG-TELSDCT
APLSVKDNDKWVDTHVGKTTEIHLKGNPTTGYMWTRVGFVGKDVLSDEI
APLTMKDNNKCLSVRVGSTLEIHLEGNPTTGYTWTRVGFVGKEMLSDEH
DISSSDSIIYFITVKPGTEITVNIKGNPTTGYSQQMIIKPN--DSIVKV
QLKPLKVGTTTIKLGYSRPWEKGKEP-LRSLTYSVVIR---------
KITGTQTGEGKIVLVYRRPWAP--NANDRTFTLKVNVQ---------
SFRAIKKGFVWVNATYNIPTTK-----DIDYYFTVVIR---------
HVTVKAAGTHAVNLTYMRPWTGPSHDSERFTVYLKAN----------
EVKALKPGKHTLSLAYGRPWVGFNAAAKRYNIHVEATA---------
LVKPRKRGHHTLELVYTRPFEGIKPENERYTLHLNVK----------
FVKPLRKGQHAVQLVYARPFEGPKPDNERYTLHLNVE----------
RFSAVGSGSTVSTIEYARYFERPPKCIFKTEIQFKVIDLPCEEIIKE
tic protozoa. EhICP2 (EAL43979), EhICP1 (EAL47869), ICP from E.
ome Trust Sanger Institute), T. cruzi (Chagasin, AJ299433), T. brucei
AK89854) were aligned using Clustal W. The putative signal sequences
al to those in EhICP2 are shown in reverse. Amino acid residues
s and amino acids involved in binding to the active cysteine are marked
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Fig. 3. Binding of EhICPs to representative CPs. The proteins that
bound to histidine-tagged EhICP were pulled down from the amoeba
lysate using HisTrap HP beads. The amoeba lysate was incubated with
EhICP1 (lane 1), EhICP2 (lane 2), or E-64 (lane 3). The EhICP-
binding proteins were boiled with 2% SDS and 2% b-mercaptoethanol
and analyzed with western blotting using anti-CP2 (A) or anti-CP5
IgG (B).
CS
re
la
tiv
e 
ac
tiv
ity
 (%
)
1       2       3       4       5
CP2
CP5
1  2  3  4  5      1  2  3  4  5 kDa
45.0
29.0
45.0
29.0
Lysate               CSB
re
la
tiv
e 
ac
tiv
ity
 (%
)
1       2       3       4       5
A
Lysate
0
50
100
150
200
0
50
100
150
200
Fig. 4. (A) Total CP activity in the amoeba lysates (2.4 lg/mL) and the
culture supernatants (CS, 60 lL/100lL reaction mixture) was mea-
sured with Z-RR-MCA as a substrate. CP activity of each transform-
ant is shown as the relative percentage of that of the CP activity in the
GFP-expressing control transformant. Means and standard deviations
of two independent experiments (in duplicates) are shown. (B) Western
blot analysis of the lysates (10.8 lg) and CSs (70 lL) using anti-CP2
and anti-CP5 IgG. Column 1 and lane 1, non-transformant; 2, N 0-HA-
EhICP1-overexpressing; 3, C 0-GFP-EhICP1-overexpressing; 4, C 0-
GFP-EhICP2-overexpressing; 5, GFP-overexpressing transformant.
Table 1
Equilibrium constant for inhibition (Ki) of recombinant ICPs
Ki (nM)
ICP1 ICP2
rCP1 0.132 ± 0.020 0.166 ± 0.011
rCP2 0.809 ± 0.087 0.950 ± 0.089
rCP5 0.590 ± 0.069 0.050 ± 0.001
E. histolytica lysate 0.027 ± 0.005 0.016 ± 0.003
These values represent means ± S.D. from three independent experi-
ments.
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uct of degradation (Fig. 2A). Both EhICPs were detected in the
lysate but not in the culture supernatant. Thus, EhICPs seem
to inhibit intracellular proteases, unlike the serine protease
inhibitor from E. histolytica, which is presumed to inhibit ser-
ine proteases extracellularly [34].
We examined whether EhICP1 and EhICP2 interact with
native CPs. Aﬃnity pull-down using recombinant EhICP1 or
EhICP2 as a bait, followed by immunoblot analysis, of ICP-
binding proteins from the trophozoite lysate revealed that both
EhICPs bound to the mature form (as predicted by the size) of
CP2 (Fig. 3A) and CP5 (Fig. 3B) [4] with a similar eﬃciency.
These data indicate that both EhICP1 and EhICP2 have a bio-
chemical property to inhibit these two major CPs in vivo.
Using the trophozoite lysate or papain as a source of CPs,
the recombinant EhICP1 and EhICP2 showed a comparable
inhibitory activity against intrinsic and heterologous CPs, Ki
of 16–27 pM for CPs in the parasite lysate (Table 1); 6.1–
10.5 pM for papain (data not shown). These Ki values are sim-
ilar to that of chagasin [14] and EhICP1 previously reported
[21]. We next examined speciﬁcity of EhICP1 and EhICP2 to-
ward CPs using three predominant CPs in the amoeba, CP1,
CP2, and CP5 (Table 1). While EhICP2 showed comparable
Ki against CP1 and CP2, the Ki of EhICP2 against CP5 was
10–90-fold lower than that against CP1 and CP2, implying
that EhICP2 might regulates CP5 activity predominantly. In
contrast, EhICP1 showed similar Ki values toward all three
CPs. Although Ki values of EhICPs against three CPs may
be inﬂuenced by diﬀerent refolding eﬃciency of recombinant
CPs, the observed 11-fold higher preference of EhICP2 to
CP5 over CP1 and CP2 is remarkable. It is conceivable that
a CP predominantly inhibited by ICP2 is not exclusively CP5
because CP5 is not present in E. dispar, which possesses ICP2.
To understand the inhibitory mechanisms of EhICPs, we as-
sessed the molar ratio of EhICPs to CPs in the amoeba lysate.
Given that EhICPs possess heat stability like chagasin [14], the
molar concentration of EhICPs in the boiled lysate was
titrated with papain. Similarly, the concentration of totalCPs was titrated with E-64. The concentrations of the total
EhICPs and CPs were 1.41 ± 0.61 nM and 1.55 ± 0.17 lM
per lg/mL (means ± standard deviation in triplicate), respec-
tively; the molar ratio of ICPs to CPs was approximately
1:1100. This value is lower than the ratio of chagasin to cruzi-
pain (1:50) [20].
In order to examine a biological role of EhICPs, we exam-
ined total CP activity of the amoeba transformants that
Fig. 5. Immunoﬂuorescence imaging of EhICP1, EhICP2, and CP5
before and after ingestion of erythrocytes. C 0-HA-CP5-overexpressing
(A) or N 0-HA-EhICP1-overexpressing transformants (B) were stained
with anti-EhICP2 IgG (green) (9.6 lg/mL) and anti-HA Mab (red)
(2 lg/ml) in the absence of erythrocytes (upper panels) or after
incubation with erythrocytes for 10 min (lower panels). In (A),
vacuoles or phagosomes associated with both EhICP2 and CP5 are
depicted by yellow or white arrowheads, respectively. In (B), EhICP2-
associated vacuoles or phagosomes are indicated by yellow or white
arrowheads, respectively. (C) C 0-HA-CP5-overexpressing transfor-
mants were stained with anti-HA Mab (green) and Lysotracker
RED (red) in the absence of erythrocytes.
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to the GFP-overexpressing control transformant, CP activity
in the lysate of the EhICP-overexpressing transformants
reduced signiﬁcantly. CP activity in the lysate of the N 0-HA-
tagged EhICP1 and C 0-GFP-tagged EhICP2 transformants de-
creased to 43.8 ± 16.3% and 41.3 ± 30.3% (means ± standard
deviation) of the GFP-overexpressing transformant, while
CP activity in the C 0-GFP-tagged EhICP1 transformant
decreased to 13.4 ± 7.4% of the control (Fig. 4A). CP activity
in the lysate of the non-transformant was comparable to that
of the GFP-overexpressing transformant. Similarly, total CP
activity in the culture supernatant of the EhICP-overexpress-
ing transformants reduced by 72–85%; CP activity secreted
into the culture by the N 0-HA-tagged EhICP1, C 0-GFP-tagged
EhICP1, or C 0-GFP-tagged EhICP2-overexpressing trans-
formant was 27.9 ± 10.5, 15.2 ± 2.9, or 17.0 ± 1.9% of the
control GFP-expressing transformant (Fig. 4A). We roughly
estimated the relative amount of intrinsic and exogenous
EhICP1 and EhICP2 in the EhICP-overexpressing transfor-
mants by densitometric scanning of immunoblots (Fig. 2).
The intensity of exogenous N 0-HA EhICP1 or C 0-GFP-tagged
EhICP1was approximately 2–5-fold less than that of endoge-
nous EhICP1, while the intensity of C 0-GFP-tagged EhICP2
was slightly less than that of endogenous EhICP2.
The fact that less than 2-fold overexpression of EhICPs re-
sulted in the reduction of up to 90% CP activity may indicate,
together with the fact that the amount of EhICP is 1100-fold
less than that of CP (see above), that EhICPs may inhibit
CP activity not only by binding, but also by further leading
to irreversible inactivation or degradation. However, the pre-
mise that binding of ICPs to CPs leading to intracellular deg-
radation of CPs is the major mode of ICP action is unlikely
because the amount of the intracellular CP remained un-
changed. It is worth noting that an additional faint band ap-
peared above the mature form (Fig. 4B, left bottom panel,
lanes 2–4), which likely corresponds to a partially-processed
form of CP5. This may suggest that binding of EhICPs inter-
feres with the processing and maturation of CPs. Alternatively,
EhICPs may be a receptor of CPs and mediate transport of CP
by shuttling between the trans-Golgi and late endosomes/lyso-
somes. We previously demonstrated that transport of CP is
regulated in part by the interaction of Rab7A and the retro-
mer-like complex [28]. However, identity of a putative hydro-
lase receptor(s) remained unclear because a homolog of
Vps10p is absent in this organism [28]. An applausable hypoth-
esis that EhICPs function as a CP receptor needs to be con-
ﬁrmed by demonstrating an interaction of EhICPs and the
retromer-like complex. In this scenario, overexpression of
EhICPs could deprive the retromer-like complex, and conse-
quently inhibit recycling of the CP receptor and maturation
and sorting of CPs.
We examined the expression of CP2 and CP5 by Western
Blotting to conﬁrm that CP expression per se was not inﬂu-
enced by EhICP overexpression (Fig. 4B). The estimated
amount of the mature form of both CP2 and CP5 in the
EhICP-overexpressing transformants was comparable to that
in the non-transformant and the control GFP-expressing
transformant, suggesting that overexpression of EhICPs did
not inhibit synthesis of CP mRNA and protein per se. As men-
tioned above, the ratio of EhICPs to CPs is 1:1100, indicating
that EhICPs are not able to inhibit CP activity simply by direct
binding. In addition, the precursor form of CP5 was detectedin the EhICP-overexpressing transformants, suggesting that
EhICPs may regulate the processing of CP5. Since the expres-
sion of individual CPs is apparently regulated independently
(see Section 1; [8,9]), not-yet-identiﬁed positive and/or negative
regulators other than EhICPs must play a role in the regula-
tion of CP activity.
We next investigated the localizations of EhICP1, EhICP2,
and CP5 with indirect immunoﬂuorescence imaging (Fig. 5).
In steady state, i.e., in the absence of red blood cells, EhICP2
was localized in the vesicles and vacuoles distributed across the
cytoplasm, and partially, if not perfectly, colocalized with CP5
(Fig. 5A, yellow arrowheads). CP5 was colocalized with Lyso-
tracker RED, a membrane-diﬀusible probe accumulated in
acidiﬁed organella (Fig. 5C). Thus, the majority of EhICP2
and CP5 were localized in lysosomes under steady-state condi-
tions. After erythrophagocytosis both EhICP2 and CP5 were
transported to the phagosomes (Fig. 5A, white arrowheads).
Although care should be taken to extrapolate these results to
CPs in general, these data suggest, together with our previous
report on the lysosome-to-phagosome transport of CP2 [26],
that EhICP2 has a potential to inhibit two major CPs in
CP5
Hgl
NifU
EhICP1
EhICP2
kDa
14.3
29.0
20.1
14.3
kDa
45.0
29.0
66.4
45.0
29.0
190
125
1 2 3 4 1 2 3 4
Fig. 6. Cellular fractionation of EhICP1 and EhICP2 The lysate,
produced by mechanical homogenization with a Dounce homogenizer,
was separated into the supernatant (lane 1) and pellet (lane 2) by
centrifugation at 5000 · g for 10 min. The 5000 · g supernatant was
subsequently centrifuged at 100000 · g for 30 min to obtain the
supernatant (lane 3) and pellet (lane 4). These fractions (12 lg each)
were subjected to immunoblot analyses using the following antibodies:
EhICP1, EhICP2, CP5, Gal/GalNAc lectin heavy subunit (Hgl, [31]),
and NifU [30].
D. Sato et al. / FEBS Letters 580 (2006) 5306–5312 5311phagosomes: CP2 and CP5. The localization of epitope-tagged
CP5 or EhICP1 was indistinguishable from that of the corre-
sponding endogenous proteins (data not shown). In contrast,
EhICP1 was localized in the cytosol (Fig. 5B, yellow and white
arrowheads), which contradicts the previous report [21,33].
The cytosolic localization of EhICP1 did not change after
phagocytosis Fig. 6.
To verify the distinct localization of EhICP1 and EhICP2,
the amoeba lysates were subjected to diﬀerential centrifugation
at 5000 · g and 100000 · g, and immunoblot analyses with
antibodies against EhICP1, EhICP2, CP5, Gal/GalNAc lectin
heavy subunit [31], and NifU (a cytosolic scaﬀold protein nec-
essary for the biosynthesis of iron–sulfur clusters [30]). EhICP2
was detected in both the 100000 · g pellet and the 5000 · g pel-
let fractions (and also the 5000 · g supernatant), similar to
CP5, while EhICP1 was associated with the 100000 · g super-
natant, similar to NifU. CP5 was detected mainly in the
5000 · g pellet fractions, and also in the 100000 · g pellet,
while Hgl or NifU was detected mainly in the 100000 · g pellet
(and also the 5000 · g supernatant) or the 100000 · g superna-
tant fraction (and also the 5000 · g supernatant), consistent
with the premise that Hgl or NifU is localized to the plasma
(and vesicular) membrane [36] or the cytosol [30], respectively.
These data agreed well with the results of the immunoﬂuores-
cence studies, and are consistent with the notion that EhICP1
and EhICP2 are localized to distinct compartments.
Despite the fact that the two EhICPs were capable of bind-
ing to and inhibiting various CPs in vitro and in vivo, as shown
by in vitro inhibition, pull-down assays, and overexpression,
the distinct localization of the two EhICPs, demonstrated by
cellular fractionation and immunoﬂuorescence studies, sug-
gests that the site of inhibition is likely diﬀerent between the
two EhICPs. We propose that EhICP2 inhibits CPs in late
endosomes and lysosomes, while EhICP1 inhibits CPs prior
to entry to the secretory pathway. Since newly synthesized
CPs are inactive before entry into the secretory pathway due
to the pro-domain, which acts as an inhibitor, inhibition of
CPs via EhICP1 binding is unnecessary. EhICP1 may preventCPs from damaging the cell in case where some precursor CPs
are activated incorrectly in the cytosol. An alternative explana-
tion is that EhICP1 could protect the cell from active CPs re-
leased from ‘‘leaky’’ lysosomes, perhaps under certain stress
conditions.
The transcriptional analysis of the trophozoites isolated
from the mouse colon demonstrated that the expression of nei-
ther EhICP1 nor EhICP2 signiﬁcantly changed upon animal
infection [8]. This is consistent with the notion that regulators
other than EhICPs are also involved in the control of CP. The
elucidation of the molecular mechanisms of regulation, pro-
cessing, activation, and transport of CP mediated by EhICPs
should help us in the understanding of the pathogenicity of
amoebiasis.
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